首页> 外文期刊>Journal of receptor and signal transduction research >Shape and pharmacophore-based virtual screening to identify potential cytochrome P450 sterol 14α-demethylase inhibitors
【24h】

Shape and pharmacophore-based virtual screening to identify potential cytochrome P450 sterol 14α-demethylase inhibitors

机译:基于形状和药效团的虚拟筛选,以鉴定潜在的细胞色素P450甾醇14α-脱甲基酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Sterol 14α-demethylase (CYP51) is a cytochrome P450 heme thiolate containing enzyme involved in biosynthesis of membrane sterols, including sterol in animals, ergosterol in fungi, and a variety of C24-modified sterols in plants and protozoa. Several clinical drugs have been developed to reduce the impact of fungal diseases, but their clinical uses have been limited by the emergence of drug resistance and insufficiencies in their antifungal activity. Therefore, in order to identify potential CYP51 inhibitors, we have implemented a virtual screening (VS) protocol by using both phase shape and pharmacophore model (AHHRR) against Asinex, ChemBridge and Maybridge databases. A filtering protocol, including Lipinski filter, number of rotatable bonds and different precisions of molecular docking was applied in hits selection. The results indicated that both shape-based and pharmacophore-based screening yielded the best result with potential inhibitors. The searched compounds were also evaluated with ADME properties, which show excellent pharmacokinetic properties under the acceptable range. We identified potential CYP51 inhibitors for further investigation, they could also be employed to design ligands with enhanced inhibitory potencies and to predict the potencies of analogs to guide synthesis/or prepare synthetic antifungal analogs against CYP51.
机译:甾醇14α-脱甲基酶(CYP51)是一种含有细胞色素P450血红素硫醇盐的酶,参与膜固醇(包括动物固醇,真菌中的麦角固醇以及植物和原生动物中各种C24修饰固醇)的生物合成。已经开发了几种临床药物以减少真菌疾病的影响,但是由于耐药性的出现和抗真菌活性的不足,限制了它们的临床用途。因此,为了鉴定潜在的CYP51抑制剂,我们已经通过针对Ainex,ChemBridge和Maybridge数据库使用相形状和药效团模型(AHHRR)实施了虚拟筛选(VS)方案。筛选方案包括Lipinski过滤器,可旋转键的数量和分子对接的不同精度在命中选择中应用。结果表明,基于形状和基于药效团的筛选均获得了潜在抑制剂的最佳结果。所搜索的化合物还具有ADME性能,在可接受的范围内显示出优异的药代动力学性能。我们确定了潜在的CYP51抑制剂以作进一步研究,它们也可用于设计具有增强抑制能力的配体,并预测类似物的能力以指导合成/或制备针对CYP51的合成抗真菌类似物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号